China innovative-drug stocks rally; Zhongheng Group hits limit-up

The breadth of the move — a limit-up leader plus double-digit and mid-single-digit gainers across several names — points to a sector-wide bid rather than an idiosyncratic story at any one company, which is the more meaningful signal for onshore innovative-drug exposure. Because the item offers no stated catalyst, the rally reads as momentum and positioning in a theme that has already been running. The open question is whether this broadening participation holds once the initial surge fades, or whether it proves to be a short-lived rotation with no fundamental driver behind it.